| Outcome Measures: |
Primary: Kidney Transplant Eligibility, Proportion either listed for kidney transplant at 9 months or meeting the following kidney transplant candidacy criteria for A1c (\<9%) and obesity (BMI \<35 kg/m2 or BMI 35-40 kg/m2 with waist circumference \<120 cm), Ascertained at the end of 9 months | Secondary: Change in Hemoglobin A1c (HgbA1c), HgbA1c will be collected using routine procedures and measured on the same day at the central Geisinger laboratory by Turbidimetric inhibition immunoassay., From baseline to 9 months|Change in BMI, Weight will be measured at each study visit in light clothing without shoes by trained, certified staff using a calibrated, digital scale. Scales will be calibrated annually. Height will be measured at the initial study visit to the nearest 0.1 cm using a calibrated, wall-mounted stadiometer without shoes on a firm, level surface, with head in the horizontal plane., From baseline to 9 months|Change in Waist Circumference, Waist circumference will be measured at each study visit to the nearest 0.1 cm using a Gulick II tape measure., From baseline to 9 months|Change in Waist-to-hip Ratio, Hip circumference will also be measured to the nearest 0.1 cm using a Gulick II tape measure, and waist-to-hip ratio will be calculated., From baseline to 9 months|Change in Body Fat Percentage, Measured using bioelectrical impedance analysis, From baseline to 9 months|New Activation on the Transplant List, Proportion of participants who were newly added to a transplant list during study period. Assessed by Geisinger kidney transplant committee (blinded to randomization assignment, independent of investigators), Assessed at end of 9 months|Receipt of Kidney Transplant, Confirmed by review of electronic health record (EHR), Assessed at end of 9 months | Other: Change in Low-Density Lipoprotein (LDL), Collected at a Geisinger lab using routine procedures and measured on the same day at the central Geisinger laboratory by spectrophotometry., Baseline to 9 months|Change in Triglycerides, Collected at a Geisinger lab using routine procedures and measured on the same day at the central Geisinger laboratory by spectrophotometry., Baseline to 9 months|Change in Systolic Blood Pressure, Automated office blood pressure (AOBP) will be measured (attended) using the OMRON 907-XL machine, with a 5-minute rest period in the seated position, followed by 3 measurements separated by 1-minute time intervals by trained research staff. Mid-arm circumference will be measured, and a cuff of appropriate size will be identified and the same size cuff will used for both visits., Baseline to 9 months|Change in Diastolic Blood Pressure, Automated office blood pressure (AOBP) will be measured (attended) using the OMRON 907-XL machine, with a 5-minute rest period in the seated position, followed by 3 measurements separated by 1-minute time intervals by trained research staff. Mid-arm circumference will be measured, and a cuff of appropriate size will be identified and the same size cuff will used for both visits., Baseline to 9 months|Change in Albuminuria Among Subset of Participants Without End-stage Kidney Disease, Testing at the central Geisinger laboratory, using immunoturbidimetry (albumin) and Jaffe/Enzymatic (Urine Creatinine), Baseline to 9 months|Change in Estimated Glomerular Filtration (eGFR) Rate Among Subset of Participants Without End-stage Kidney Disease, Testing at central Geisinger lab; Creatinine-based CKD-EPI equation, Baseline to 9 months|All-cause Hospitalizations, Collected using Geisinger EHR data, Entire 9-month study period|Cardiovascular Disease (CVD) Events, Collected using Geisinger EHR data using ICD codes for CVD-related hospitalizations, Entire 9-month study period|Proportion Experiencing Doubling of Creatinine or End-stage Kidney Disease, Collected using Geisinger EHR data using ICD codes, Entire 9-month study period|Proportion Experiencing Death, Collected using Geisinger EHR data, Entire 9-month study period|Proportion Experiencing Gastrointestinal Disorders, Assessed at each study visit, Entire 9-month study period|Proportion Experiencing Gallbladder Disorders, Assessed at each study visit, Entire 9-month study period|Proportion Experiencing Neoplasms, Assessed at each study visit, Entire 9-month study period|Proportion Experiencing Hepatic Events, Assessed at each study visit, Entire 9-month study period|Proportion Experiencing Allergic Reactions, Assessed at each study visit, Entire 9-month study period|Proportion Experiencing Injection-site Reactions, Assessed at each study visit, Entire 9-month study period|Proportion Experiencing Hypoglycemia Events, Assessed at each study visit, Entire 9-month study period|Proportion Experiencing Acute Pancreatitis Events, Assessed at each study visit, Entire 9-month study period
|
